1,721,301 research outputs found
Rivaroxaban, a novel option for patients with atrial fibrillation and a bioprosthetic mitral valve
No full textNo abstract availabl
PHARMACOLOGIC MODULATION OF ARACHIDONIC ACID METABOLISM IN MAN. A MINIREVIEW WITH EMPHASIS ON RADIOIMMUNOLOGICAL METHODS USED TO QUANTITATE DRUG EFFECTS.
No full textPlatelet Activation in Atherothrombosis.
No full textPlatelets are essential for primary hemostasis and repair of the endothelium, but they also play a key role in the development of acute coronary syndromes and contribute to cerebrovascular events. In addition, they participate in the process of forming and extending atherosclerotic plaques. Atherosclerosis is a chronic inflammatory process, and inflammation is an important component of acute coronary syndromes. The relation between chronic and acute vascular inflammation is unclear, but platelets are a source of inflammatory mediators, and the activation of platelets by inflammatory triggers may be a critical component of atherothrombosis. This review article describes the role of platelets..
Out-of-hospital cardiac arrest: handle with care-comment on the resuscitation outcomes consortium cardiac epidemiologic registry
No full textThe efficacy and safety of trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention
(ATPCI) study was designed to assess the potential long-term benefits of antianginal therapy after PCI.
• Approximately, 6000 patients who had had a successful PCI performed <30 days before inclusion, for stable angina or NSTE-ACS, regardless of the presence or absence of angina symptoms after the index PCI, were randomized to receive trimetazidine at the dose of 35 mg
twice daily or placebo in addition to routine post-PCI treatment, and followed for up to 4 years.
• The incidence of the primary endpoint (a composite of cardiac death, hospital admission for a cardiac event, recurrence, or persistence of
angina requiring the addition, switch, or increase of the dose of one of the antianginal drugs, or recurrent or persistent angina requiring coronary angiography) was not significantly different between the trimetazidine group [700 (23.3%) patients] and the placebo group [714
(23.7%); hazard ratio 0.98 (95% confidence interval 0.88–1.09); P 1⁄4 0.73]. Similar results were obtained in the elective and urgent PCI subgroups. Serious adverse events occurred with similar frequencies in the two treatment groups
PCSK9 inhibition: not just LDL-cholesterol knock down: a glimmer for cancer
No full textn the last few years, PCSK9 inhibitors have gained an increasing role in
the treatment of dyslipidaemias,1 since monoclonal antibodies targeting
PCSK9, namely evolocumab and alirocumab, were demonstrated to
profoundly reduce plasma LDL-cholesterol levels and the incidence of
major cardiovascular events in large randomized clinical trials of highrisk patients.2
Decline in blood pressure control trends in the US: a real step back: comment on National Health and Nutrition Examination Survey (NHANES) data
No full textThis analysis conducted by National Health and Nutrition Examination Survey (NHANES) investigated the changes in blood pressure (BP)
control rates between 1999–2000 and 2017–2018, spanning ten 2-year cycles.
• The primary outcome of BP control was defined as systolic BP level <140 mm Hg and diastolic BP level <90 mm Hg. The secondary outcomes were hypertension awareness and use of antihypertensive medication.
• Among the included 18 262 hypertensive adults (from a total sample of 51 761 individuals), the age-adjusted estimated proportion of adults
with controlled BP increased from 1999–2000 through 2007–2008, remained stable from 2007–2008 through 2013–2014, and decreased
from 2013–2014 through 2017–2018. BP control rates were higher among older compared to younger participants (50% among those
aged 45–64 years vs. 37% among those aged 18–44 years).
• BP control, awareness, and antihypertensive medication use were more likely among non-Hispanic white adults, those with health insurance, and those who were undergoing regular follow-up visits.
• Temporal trends in age-adjusted proportion of adults with hypertension and controlled BP did not change using the tighter thresholds recommended by 2017 American College of Cardiology/American Heart Association (ACC/AHA) BP guidelines
The second life of the ambiguous angiotensin-converting enzyme 2 as a predictive biomarker for cardiometabolic diseases and death
No full textThis nested case-cohort analysis from the multinational Prospective Urban Rural Epidemiology (PURE) study analyzed plasma levels of a
component of the renin-angiotensin system (RAS), angiotensin-converting enzyme 2 (ACE2), as a predictor of cardiovascular (CV) events
[CV mortality, myocardial infarction (MI), stroke, heart failure (HF)] and all-cause mortality.
• From a total population of 55 246 PURE participants from 14 countries across five continents, the authors took a random sample (the subcohort). The final sample consisted of participants who were members of the subcohort (n 1⁄4 5084) and those who had incident events
outside the subcohort (n 1⁄4 5669). The median follow-up was 9.4 years (IQR, 8.7–10.5)
A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19
No full textNo abstract availabl
Do VERTIS-CV trial results question a class-effect of cardiovascular protection with sodium-glucose cotransporter 2 inhibitors?
Full text linkVERTIS-CV was planned according to the Food and Drug
Administration (FDA) former guidelines to assess the CV safety of
new glucose-lowering drugs (recently updated to evaluate safety more
broadly). Therefore, this study was originally designed and powered to
show non-inferiority of ertugliflozin compared to placebo with respect
to CV outcomes in high-risk patients with type 2 diabetes. From this
point of view, the ‘mission’ was accomplished since VERTIS-CV results
showed non-inferiority of ertugliflozin compared to placebo.
However, based on previous studies showing positive effects of other
SGLT2i on CV and renal outcomes, the VERTIS-CV protocol had
been amended to reflect a doubling of the original sample size and inclusion of efficacy objectives for superiority
- …
